TWIST1 and bladder transitional cell carcinoma: Our study demonstrates that the sensitivity and specificity of TWIST1/Vimentin promoter methylation in urine samples for differentiating bladder urothelial carcinoma (BUC) from benign diseases and healthy controls reached 78% and 83%, respectively.